Some reported anti-tumor mechanisms behind the HDAC and MEK inhibitor combination in other cancer studies include enhanced production of ROS (reactive oxygen species) [42], activation of cell-cycle inhibitors [45], increased apoptosis and deregulated survival pathways [59]. The gene discussed is HDAC9; the disease is cancer.